Jury Says Roche's Mircera Infringed Amgen Patents

Law360, New York (October 23, 2007, 12:00 AM EDT) -- A federal jury handed Amgen Inc. a big victory Tuesday, ruling that its patents were infringed by Roche Holding AG's generic anemia drug Mircera.

In its verdict, the jury in the U.S. District Court for the District of Massachusetts found that Mircera had literally infringed nine of Amgen's patent claims and had infringed another claim under the doctrine of equivalents. The jury also found that all of Amgen's patent claims were valid.

“We're thrilled with it,” said Bill Gaede, a partner with McDermott Will & Emery...
To view the full article, register now.